Back to top
more

Vaxcyte (PCVX)

(Delayed Data from NSDQ)

$73.44 USD

73.44
484,371

+2.50 (3.52%)

Updated Jun 5, 2024 04:00 PM ET

After-Market: $73.45 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know

by Zacks Equity Research

Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.

The Zacks Analyst Blog Highlights HEICO, Constellation Energy, Inter Parfums, Apellis Pharmaceuticals and Vaxcyte

by Zacks Equity Research

HEICO, Constellation Energy, Inter Parfums, Apellis Pharmaceuticals and Vaxcyte are part of the Zacks top Analyst Blog.

Why Vaxcyte (PCVX) Might Surprise This Earnings Season

by Zacks Equity Research

Vaxcyte (PCVX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Nalak Das headshot

5 Stocks to Buy That Are Poised to Beat on Earnings This Week

by Nalak Das

We have narrowed our search to five stocks that are poised to beat on earnings this week. These are: HEi, CEG, IPAR, APLS, PCVX.

Codexis (CDXS) Transfers Leasing Rights to Vaxcyte, Stock Up

by Zacks Equity Research

Codexis (CDXS) transfers the leasing rights of its San Carlos, CA location to Vaxcyte to focus on technology development, inducing cost savings, to extend its cash runway to mid-2026. The stock rises 7%.

Ekta Bagri headshot

5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND, MESO and PBYI well amid volatility.

Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 33.33%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 33.3% in Vaxcyte, Inc. (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Vaxcyte, Inc. (PCVX) Could Rally 26.15%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 26.2% in Vaxcyte, Inc. (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Biotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides Updates

by Zacks Equity Research

Pipelines updates from Madrigal (MDGL) and Vaxcyte, (PCVX) are the key highlights of the biotech sector.

Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data

by Zacks Equity Research

Vaxcyte (PCVX) announces positive results from the mid-stage study of its 24-Valent pneumococcal conjugate vaccine candidate, VAX-24, in adults aged 65 and older.

Recent Price Trend in Vaxcyte, Inc. (PCVX) is Your Friend, Here's Why

by Zacks Equity Research

Vaxcyte, Inc. (PCVX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Vaxcyte (PCVX) Completes Enrollment in Pneumococcal Disease Study

by Zacks Equity Research

Vaxcyte (PCVX) enrolls the last patient in the phase II portion of phase I/HH study, evaluating VAX-24 for preventing invasive pneumococcal disease and pneumonia in healthy adults.

Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 96%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Vaxcyte, Inc. (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Vaxcyte (PCVX) Have the Potential to Rally 89% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 89% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.